Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study.
Rodríguez de Dios N, Couñago F, Murcia-Mejía M, Rico-Oses M, Calvo-Crespo P, Samper P, Vallejo C, Luna J, Trueba I, Sotoca A, Cigarral C, Farré N, Manero RM, Durán X, Gispert JD, Sánchez-Benavides G, Rognoni T, Torrente M, Capellades J, Jiménez M, Cabada T, Blanco M, Alonso A, Martínez-San Millán J, Escribano J, González B, López-Guerra JL. Rodríguez de Dios N, et al. Among authors: samper p. J Clin Oncol. 2021 Oct 1;39(28):3118-3127. doi: 10.1200/JCO.21.00639. Epub 2021 Aug 11. J Clin Oncol. 2021. PMID: 34379442 Clinical Trial.
Treatment Design and Rationale for a Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for SCLC: PREMER Trial on Behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Radiation Oncology Group-Radiation Oncology Clinical Research Group.
Rodríguez de Dios N, Couñago F, López JL, Calvo P, Murcia M, Rico M, Vallejo C, Luna J, Trueba I, Cigarral C, Farre N, Manero RM, Durán X, Samper P. Rodríguez de Dios N, et al. Among authors: samper p. Clin Lung Cancer. 2018 Sep;19(5):e693-e697. doi: 10.1016/j.cllc.2018.05.003. Epub 2018 May 10. Clin Lung Cancer. 2018. PMID: 29891263 Clinical Trial.
Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
Valero J, Peleteiro P, Henríquez I, Conde A, Piquer T, Lozano A, Soler CC, Muñoz J, Illescas A, Jove J, Flores MM, Baquedano J, Diezhandino P, de Celis RP, Pardo EH, Samper P, Villoslada I, Eguiguren M, Millan V. Valero J, et al. Among authors: samper p. Clin Transl Oncol. 2020 Aug;22(8):1378-1389. doi: 10.1007/s12094-019-02274-w. Epub 2020 Jan 27. Clin Transl Oncol. 2020. PMID: 31989474
The white book of radiation oncology in Spain.
Herruzo I, Romero J, Palacios A, Mañas A, Samper P, Bayo E, Guedea F; Libro Blanco de Oncología Radioterápica. Herruzo I, et al. Among authors: samper p. Clin Transl Oncol. 2011 Jun;13(6):385-95. doi: 10.1007/s12094-011-0672-3. Clin Transl Oncol. 2011. PMID: 21680299
Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures.
Zamora V, Garin O, Suárez JF, Gutiérrez C, Guedea F, Cabrera P, Castells M, Herruzo I, Fumadó L, Samper P, Ferrer C, Regis L, Pont À, Ferrer M; Multicentric Spanish Group of Clinically Localized Prostate Cancer. Zamora V, et al. Among authors: samper p. Clin Transl Radiat Oncol. 2023 Oct 29;44:100694. doi: 10.1016/j.ctro.2023.100694. eCollection 2024 Jan. Clin Transl Radiat Oncol. 2023. PMID: 38021091 Free PMC article.
Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer.
López Torrecilla J, Zapatero A, Herruzo I, Calvo FA, Cabeza MA, Palacios A, Guerrero A, Hervás A, Lara P, Ludeña Martínez B, Del Cerro Peñalver E, Nagore G, Sancho G, Mengual JL, Mira M, Mairiño A, Samper P, Pérez S, Castillo I, Martínez Cedrés JC, Ferrer E, Rodriguez S, Maldonado X, Gómez Caamaño A, Ferrer C; Grupo de Investigación GICOR-URONCOR-SEOR. López Torrecilla J, et al. Among authors: samper p. Clin Transl Oncol. 2014 May;16(5):447-54. doi: 10.1007/s12094-013-1121-2. Epub 2013 Oct 25. Clin Transl Oncol. 2014. PMID: 24682792
Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys.
Zamora V, Garin O, Pardo Y, Pont À, Gutiérrez C, Cabrera P, Gómez-Veiga F, Pijoan JI, Litwin MS, Ferrer M; Multicentric Spanish Group of Clinically Localized Prostate Cancer. Zamora V, et al. Value Health. 2021 Nov;24(11):1676-1685. doi: 10.1016/j.jval.2021.03.021. Epub 2021 Sep 8. Value Health. 2021. PMID: 34711369 Free article.
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J. de la Piedra C, et al. Among authors: samper p. Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270. Epub 2013 May 30. Br J Cancer. 2013. PMID: 23722472 Free PMC article. Clinical Trial.
34 results